JP2016510332A5 - - Google Patents

Download PDF

Info

Publication number
JP2016510332A5
JP2016510332A5 JP2015555373A JP2015555373A JP2016510332A5 JP 2016510332 A5 JP2016510332 A5 JP 2016510332A5 JP 2015555373 A JP2015555373 A JP 2015555373A JP 2015555373 A JP2015555373 A JP 2015555373A JP 2016510332 A5 JP2016510332 A5 JP 2016510332A5
Authority
JP
Japan
Prior art keywords
compound
content
pharmaceutical composition
arginine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015555373A
Other languages
English (en)
Japanese (ja)
Other versions
JP6408489B2 (ja
JP2016510332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/013120 external-priority patent/WO2014117056A1/en
Publication of JP2016510332A publication Critical patent/JP2016510332A/ja
Publication of JP2016510332A5 publication Critical patent/JP2016510332A5/ja
Application granted granted Critical
Publication of JP6408489B2 publication Critical patent/JP6408489B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015555373A 2013-01-25 2014-01-27 治療配合物(compounds) Expired - Fee Related JP6408489B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757058P 2013-01-25 2013-01-25
US61/757,058 2013-01-25
PCT/US2014/013120 WO2014117056A1 (en) 2013-01-25 2014-01-27 Therapeutic compounds

Publications (3)

Publication Number Publication Date
JP2016510332A JP2016510332A (ja) 2016-04-07
JP2016510332A5 true JP2016510332A5 (enExample) 2016-06-23
JP6408489B2 JP6408489B2 (ja) 2018-10-17

Family

ID=51228097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015555373A Expired - Fee Related JP6408489B2 (ja) 2013-01-25 2014-01-27 治療配合物(compounds)

Country Status (11)

Country Link
US (1) US10195242B2 (enExample)
EP (1) EP2948129B1 (enExample)
JP (1) JP6408489B2 (enExample)
AU (1) AU2014209162B2 (enExample)
CA (1) CA2894240C (enExample)
DK (1) DK2948129T3 (enExample)
ES (1) ES2659066T3 (enExample)
NO (1) NO2982810T3 (enExample)
PL (1) PL2948129T3 (enExample)
PT (1) PT2948129T (enExample)
WO (1) WO2014117056A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106729575A (zh) * 2017-01-25 2017-05-31 深圳市艾梵诗生物技术有限公司 具有青少年抗菌消炎、祛痘淡印功效的中药组合物、美容产品及其制备方法
WO2018148763A1 (en) * 2017-02-13 2018-08-16 Wintermute Biomedical, Inc. Anti-pathogenic therapeutic compositions
CA3115050A1 (en) * 2018-10-01 2020-04-09 Wintermute Biomedical, Inc. Therapeutic compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150052A (en) 1971-02-04 1979-04-17 Wilkinson Sword Limited N-substituted paramenthane carboxamides
US5766614A (en) * 1997-03-20 1998-06-16 Yong; Liu Burn treatment compositions containing herbal mix
JPH11269034A (ja) 1998-03-20 1999-10-05 Shiseido Co Ltd ニキビ改善用皮膚外用剤
JP2000281528A (ja) 1999-03-31 2000-10-10 Ichimaru Pharcos Co Ltd 化粧料組成物
US6841174B2 (en) * 2000-09-20 2005-01-11 Zeyad Technologies Llc Herbal compositions and treatment methods
JP2002114670A (ja) * 2000-10-02 2002-04-16 Noevir Co Ltd 抗菌性皮膚外用剤
US7288265B1 (en) * 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
GB0221697D0 (en) 2002-09-18 2002-10-30 Unilever Plc Novel compouds and their uses
CN1753968B (zh) * 2003-01-27 2010-04-28 维生素C60生化学研究公司 抗氧化组合物以及外用组合物
EP1685093B3 (en) 2003-11-21 2012-04-11 Givaudan SA N-substituted p-menthane carboxamide and use of n-substituted p-menthane carboxamides
US20120328544A1 (en) 2003-12-22 2012-12-27 Nevada Naturals, Inc. Dermatological Treatment Methods And Formulations
DE602005011437D1 (de) 2004-06-18 2009-01-15 Symrise Gmbh & Co Kg Brombeerextrakt
WO2006029893A2 (en) 2004-09-17 2006-03-23 Oystershell Nv Composition for inhibiting or preventing the formation of a biofilm
GB0423652D0 (en) 2004-10-25 2004-11-24 Univ Coventry Kit
EP1893396A2 (en) * 2005-05-09 2008-03-05 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
CN1969984B (zh) * 2006-12-07 2010-12-29 刘爱芹 一种治疗皮肤粉刺和过敏的外用药
CN101631563B (zh) * 2007-03-09 2013-07-24 大塚制药株式会社 含有流感疫苗的冻干制剂及其制备方法
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
CN101991726A (zh) * 2009-08-25 2011-03-30 肖华 一种治疗巨细胞病毒的药物组合物及其制备方法
RU2013135305A (ru) * 2010-12-28 2015-02-10 Камедис Лтд. Растительные экстракты для лечения и профилактики инфекций
CN102178842B (zh) 2011-04-27 2013-10-16 李梅华 一种治疗结核病的药物组合物及应用
BR112017002858B1 (pt) 2014-08-13 2022-01-18 Akeso Biomedical, Inc Método não terapêutico para aumentar o crescimento de um animal, uso não terapêutico de um ou mais compostos, um ou mais compostos, animal não humano ou produto animal, alimento para animais adequado para uso e suprimento de água potável para animais adequado para uso

Similar Documents

Publication Publication Date Title
EA201490647A1 (ru) Производные бензотиазол-6-илуксусной кислоты и их применение для лечения вич-инфекции
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
IN2015DN00376A (enExample)
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
IN2014MN01755A (enExample)
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
EA201491889A1 (ru) Соединения и способы для противовирусной терапии
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
MY180145A (en) Cenicriviroc compositions and methods of making and using the same
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112013019256A2 (pt) inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
NZ720328A (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
EA033054B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
WO2013142182A3 (en) Combination therapy of a mek inhibitor and igf1r inhibitor
BR112015016184A2 (pt) derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
JP2016538288A5 (enExample)